Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models

1. Introduction

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of some anticancer drugs, such as bortezomib, cisplatin, oxaliplatin, paclitaxel, thalidomide, and vincristine. The incidence of CIPN in patients varies from as low as 12.1% to as high as 96.2% depending on the chemotherapeutic agent and possibly the type of cancer in which the drug is used. Some chemotherapeutic drugs are associated with high incidence of CIPN; for example, in patients treated with oxaliplatin, it is around 72.3% (95% CI 59.7–86.8) and with paclitaxel it is around 70.8% (95% CI 43.5–98.1) [1]. Some patients who experience CIPN also experience neuropathic pain; for example, amongst patients who experienced CIPN during paclitaxel treatment, 27% of these patients had neuropathic pain [2], and neuropathic pain occurred in the majority of those treated with bortezomib [3]. Some of the symptoms of the painful CIPN, also referred to as chemotherapy-induced neuropathic pain (CINP), include hyperalgesia, allodynia, and spontaneous sensations such as burning, shooting, numbness, spasm, and prickling, and these can significantly reduce the patient’s quality of life [4–6]. Regrettably, there is a scarcity of drugs to either prevent or manage CINP. Currently, only duloxetine has a recommendation for the management of CINP, whilst other drugs used for other neuropathic pain conditions may be given because of the limited CINP treatment options [7]. Thus, studies to understand the pathophysiology and to develop novel treatment options for CINP treatment are essential.

Cannabis or cannabinoids have been reported to improve pain measures in patients with neuropathic pain [8–11]. A recent study recommends studying the effects of a cannabinoid agent, nabiximols, against CINP in a full randomised, placebo-controlled trial [12].
Phytocannabinoids, synthetic cannabinoids, and endogenous cannabinoids (endocannabinoids), such as N-arachidonoylthetanolamine (AEA, anandamide) and 2-arachidonoylglycerol (2-AG), produce their effects via activation of cannabinoid receptors, CB1 and CB2 receptors [13]. Endocannabinoids are lipid-based neurotransmitters produced on demand [14–17] from cell membrane phospholipid precursors [18, 19] through various pathways [20]. Endocannabinoid homeostasis is maintained by transporters that transport AEA and 2-AG from the synaptic space back into the cells or by enzymes that degrade the endocannabinoids. Fatty acid amide hydrolase (FAAH) hydrolyses AEA to arachidonic acid and ethanolamine [21]. Monoacylgllycerol lipase (MGL) hydrolyses 2-AG to arachidonic acid and glycerol [22, 23].

In this minireview, changes that occur in the endocannabinoid system during CINP and the possibility of targeting the endocannabinoid enzymes and cannabinoid receptors to manage CINP will be discussed. This minireview deals only with results obtained from animal studies.

2. Methods and Selection of Articles to Include in the Analysis of Endocannabinoid Expression and Compounds Utilising the Endocannabinoid System to Prevent or Treat CINP in Animal Models

The U.S. National Library of Medicine, Washington, DC (MEDLINE-PubMed), was used to search for appropriate papers for this study, without limitations of date of publication, using different combinations of the words or phrases: chemotherapy-induced neuropathy, chemotherapy-induced neuropathic pain, cannabinoid, endocannabinoid, pain, expression, cisplatin, paclitaxel, and vincristine. The search strategy was designed to include any published paper that examined the expression of endocannabinoids in animal models of CINP and/or evaluated the use of cannabinoids or drugs that prevent or treat established hyperalgesia, hypersensitivity, or allodynia in animal models of CINP in a cannabinoid receptor-dependent manner. Articles that were found in more than 1 search combination were counted only once. Studies that did not use animals, did not evaluate CINP, or evaluated noncannabinoid compounds without using cannabinoid receptor antagonists, reviews, commentaries, and in vitro studies were excluded.

From the electronic search, a total of 48 articles were identified, and of these, 20 articles were excluded because they were reviews, human studies, in vitro studies, did not evaluate CINP, and evaluated noncannabinoid compounds without using cannabinoid receptor antagonists. Twenty-eight articles fulfilled the inclusion and exclusion criteria described above and are discussed in the sections below.

3. Expression of Endocannabinoids during Chemotherapy-Induced Neuropathic Pain

Four studies were found that measured the expression of the endocannabinoids 2-AG and AEA in rodent models of CINP [24–27]. All these studies were done in male rodents of cisplatin CINP (Table 1). Treatment of mice with cisplatin reduced the expression of AEA but not 2-AG in the paw skin [25, 27]. Guindon et al. measured the expression of endocannabinoids in the spinal cord and paw skin in rats with cisplatin-induced mechanical and cold allodynia [24]. Rats treated with cisplatin had increased levels of 2-AG and AEA in the lumbar spinal cord, whilst 2-AG, but not AEA, was decreased in the dorsal hind paw skin [24]. In another study, Khasabova et al. showed that treatment of mice with cisplatin resulted in decreased levels of AEA and 2-AG in the paw skin and dorsal root ganglia (DRGs), increased levels of AEA and 2-AG in the spinal cord, but no change in the brain [26]. These studies suggest there is a specific deficiency of endocannabinoids in the periphery during CINP. Thus, increasing the levels of these endocannabinoids in the periphery by inhibiting either their degradation or transport from the synaptic space back into the cells is a potential therapeutic target for managing CINP.

4. Effect of Inhibitors of Endocannabinoid Metabolism on Chemotherapy-Induced Neuropathic Pain

Taking into consideration that FAAH and MGL degrade the endocannabinoids, their inhibitors have been evaluated in animal models of CINP. All of the five studies carried out utilised male rodents of CINP (Table 2). An FAAH inhibitor ST4070 suppressed established mechanical allodynia in rats with vincristine-induced mechanical allodynia [28]. Another FAAH inhibitor URB597 delayed the onset and decreased the magnitude of mechanical and heat hyperalgesia and also suppressed established mechanical and thermal hyperalgesia in mice with cisplatin-induced hyperalgesia in a CB1, but not CB2, receptor-dependent manner [25]. Two FAAH inhibitors URB597 and URB937 and an MGL inhibitor JZL184 suppressed established cisplatin-induced mechanical and cold allodynia in rats. The antiallodynic effects of the FAAH inhibitors and MGL inhibitor were blocked by CB1, but not CB2, receptor antagonists [24]. In mice, peripheral administration of low doses of JZL184 was found to prevent the development of cisplatin-induced mechanical hyperalgesia in a CB1 receptor, but not CB2 receptor, dependent manner [26]. URB597 and JZL184 were also reported to suppress paclitaxel-induced mechanical and cold allodynia in mice [29]. These studies show that FAAH and MGL inhibitors can both prevent the development and attenuate established CINP symptoms mainly in a CB1 receptor-dependent manner.

5. Effect of Cannabinoid Agonists on Chemotherapy-Induced Neuropathic Pain

The majority of the studies (21 studies) on cannabinoids and CINP in animal models evaluated the effects of agonists via CB1 and CB2 receptors (Table 3). The use of nonselective CB1/CB2 agonists was found in 11 studies, CB1 receptor-selective agonists in 2 studies, and CB2 receptor-selective agonists in 11 studies. Some studies evaluated drugs in more
than one of the categories of selectivity for CB receptors. All the studies that stated the gender (19 out of 21) conducted on CB receptor agonists and CINP utilised male rodents (Table 3). Two studies did not state the gender of the mice used (Table 3).

Nonselective CB1/CB2 receptor agonists such as the endocannabinoids 2-AG and AEA, CP55,940, Δ9-tetrahydrocannabinol (THC), and WIN 55,212-2 were reported to prevent the development and/or suppress established symptoms of CINP in mice and rats. NX he endocannabinoids 2-AG and AEA suppressed established cisplatin-induced mechanical hyperalgesia in mice in a CB1, but not CB2, receptor-dependent manner [25, 26]. The phytocannabinoid THC was found to suppress established mechanical and cold allodynia induced by either cisplatin or paclitaxel in mice [30, 31]. However, the role of CB receptors in the activity of THC against CINP was not investigated. THC failed to prevent the development of cisplatin-induced mechanical allodynia [31]. A synthetic nonselective CB receptor agonist CP55,940 suppressed paclitaxel-induced allodynia in mice, via both CB1 and CB2 receptor-dependent mechanisms, but the CB2 receptor-dependent mechanism was only observed at high doses of CP55,940 in CB1 receptor-deficient mice [32]. The nonselective CB receptor agonist used most on CINP in rodents is WIN 55,212-2. WIN 55,212-2 both prevented the development and suppressed established CINP, in a manner which was CB1 and CB2 receptor-dependent [33–39]. It has both systemic and local effects; however, its local effects appear to be CB1, but not CB2, receptor dependent [38]. Several studies show that

### Table 1: Expression of endocannabinoids in animal models of CINP.

| Chemotherapy drug | CINP model | Expression of endocannabinoids | Reference |
|-------------------|------------|---------------------------------|-----------|
| Cisplatin         | Male C3H/HeN mice | Mechanical and heat hyperalgesia | Plantar paw skin, Lumbar spinal cord, Dorsal hind paw skin | Decrease in AEA but no change in 2-AG | [25] |
| Cisplatin         | Male SD rats | Mechanical and cold allodynia | Plantar paw skin, DRGs | Both 2-AG and AEA increased | Both 2-AG and AEA decreased | [24] |
| Cisplatin         | Male C3H/HeN mice | Mechanical hyperalgesia | Lumbar spinal cord, Midbrain | Both 2-AG and AEA decreased | Both 2-AG and AEA increased | [26] |
| Cisplatin         | Male C3H/HeN mice | Mechanical allodynia | Plantar paw skin | Decrease in AEA but no change in 2-AG | [27] |

2-AG, 2-arachidonoylglycerol; AEA, N-arachidonoylethanolamine (anandamide); SD, Sprague-Dawley.

### Table 2: Effects of inhibitors of enzymes that degrade endocannabinoids in animal models of CINP.

| Chemotherapy drug | CINP model | Inhibitor of enzymes that degrade endocannabinoids | Effects | Effects of CB receptor antagonists on the activity of the compound | Reference |
|-------------------|------------|--------------------------------------------------|---------|---------------------------------------------------------------|-----------|
| Vincristine       | Male SD rats | FAAH inhibitor ST4070 | Suppressed established mechanical allodynia | No antagonists were used against vincristine | [28] |
| Cisplatin         | Male C3H/HeN mice | FAAH inhibitor URB597 | Suppressed established mechanical and thermal hyperalgesia | CB1 antagonist AM281 antagonised | [25] |
| Cisplatin         | Male SD rats | FAAH inhibitors URB597 and URB937 | Suppressed established mechanical and cold allodynia | CB1 antagonist AM630 had no effect | [24] |
| Cisplatin         | Male C3H/HeN mice | MGL inhibitor JZL184 | Prevented the development of mechanical hyperalgesia | CB1 receptor antagonist AM281 antagonised | [26] |
| Paclitaxel        | Male CD1 and C57BL/6J mice | URB597 and JZL184 | Suppressed mechanical and cold allodynia | CB2 receptor antagonist AM630 had no effect | [29] |

FAAH, fatty acid amide hydrolase; MGL, monoacylglycerol lipase; SD, Sprague-Dawley.
Table 3: Effects of CB receptor agonists in animal models of CINP.

| Chemotherapy drug | CINP model | CB receptor agonist | Effects | Effects of CB receptor antagonists on the activity of the compound | Reference |
|-------------------|------------|---------------------|---------|---------------------------------------------------------------|-----------|
| **Nonselective CB1/CB2 receptor agonists** | | | | | |
| Cisplatin | Male C3H/HeN mice | 2-AG | Suppressed established mechanical hyperalgesia | CB1 receptor antagonist AM281 antagonised | [26] |
| Cisplatin | Male C3H/HeN mice | AEA | Suppressed established mechanical hyperalgesia | CB2 receptor antagonist AM630 had no effect | |
| Paclitaxel | CD1 and C57BL/6J mice | THC | Suppressed established mechanical and cold allodynia | CB1 antagonist AM281 antagonised | [25] |
| Cisplatin | Male C57BL/6 mice | THC | Did not prevent the development of mechanical allodynia | CB2 antagonist AM630 had no effects | |
| Paclitaxel | CD1 and C57BL/6J mice | CP55,940 | Suppressed established mechanical and cold allodynia | | |
| Paclitaxel | Male Wistar rats | WIN | Suppressed established thermal hyperalgesia and mechanical alllodynia | CB2 antagonist AM630 antagonised | [32] |
| Vincristine | Male SD rats | WIN | Suppressed established mechanical alldodynia | Both CB1 antagonist SR141716A and CB2 antagonist SR144528 antagonised | [33] |
| Cisplatin | Male Wistar rats | WIN | Prevented the development of mechanical alldodynia | No antagonists were used | [34] |
| Paclitaxel | Male Wistar rats | WIN | Prevented the development of mechanical, allodynia | | |
| Cisplatin | Male Wistar rats | WIN | Prevented the development of mechanical allodynia | No antagonists were used | [35] |
| Cisplatin | Male Wistar rats | WIN | Suppressed established mechanical alldodynia | No antagonists were used | [36] |
| Paclitaxel | Male SD rats | WIN | Prevented the development of mechanical and cold allodynia | No antagonists were used | |
| **CB1 receptor-selective agonists** | | | | | |
| Cisplatin | Male Wistar rats | ACEA | Suppressed established mechanical alldodynia | CB1 receptor antagonist AM251 antagonised | [37] |
| Paclitaxel | Male CD1 and C57BL/6J mice (CB1 PAM) | GAT211 | Suppressed mechanical and cold allodynia | CB1 receptor antagonist AM251 antagonist | [38] |
| **CB2 receptor-selective agonists** | | | | | |
| Vincristine | Male SD rats | AM1241 | Suppressed established mechanical allodynia | Both CB1 antagonist AM251 and CB2 antagonist SR144528 antagonised | [39] |
| Paclitaxel | Male SD rats | AM1241 and AM1714 | Suppressed established mechanical allodynia | CB2 receptor antagonist AM630 did not reliably antagonise both mechanical and cold alldodynia | [40] |
nonselective CB receptor agonists attenuate CINP in a CB1, but not CB2, receptor-dependent manner most likely because CB1 receptors are expressed at higher levels in the nervous system than CB2 receptors, while CB2 receptors are expressed mainly in immune cells and the levels increase in the nervous system during injury. Therefore, when nonselective CB receptor agonists are used, the effects on CB1 receptors are more likely to be predominant.

A CB1 receptor-selective agonist ACEA was found to prevent the development of cisplatin-induced mechanical allodynia in rats, when administered either locally or systemically [38]. However, various problems are associated with CB1 receptor activation such as physical dependence, withdrawal adverse effects, and development of tolerance [29, 30]. A novel CB1 positive allosteric modulator (PAM), GAT211, was found to suppress paclitaxel-induced cold and mechanical allodynia in mice without producing the cardinal signs of CB1 activation, physical dependence or tolerance, which were produced by WIN 55,212-2, an orthosteric cannabinoid agonist [29].

Various CB2 receptor-selective agonists have been reported to prevent the development and/or suppress established symptoms of CINP in mice and rats. The aminoalkylindole cannabinoid AM1241 and the cannabiolactones AM1710 and AM1714 were found to prevent the development and suppress established mechanical and cold allodynia induced by cisplatin, paclitaxel, or vincristine in rodents in a CB2, but not CB1, receptor-dependent manner [30, 34, 39, 40, 41]. Other CB2 receptor-selective agonists MDA7, MDA19, JWH133, and LY2828360 were reported to prevent the development and suppress established paclitaxel-induced mechanical and cold allodynia [38, 42–46]. The CB2 receptor-dependent antiallodynic effects were demonstrated by blocking the effects of MDA7 and JWH133 by CB2 receptor antagonists [38, 43], whilst the other studies did not utilise antagonists. LY2828360 suppressed paclitaxel-induced allodynia without producing tolerance [46], β-Caryophyllene (BCP), a CB2 receptor-selective agonist found in many essential oils including clove oil and Cannabis sativa essential oil [48], prevented the development and attenuated established paclitaxel-induced mechanical allodynia in mice in a CB2, but not CB1, receptor-dependent manner [47]. Some of the advantages of CB2 receptor-selective agonists such as AM1710, over nonselective CB1/CB2 receptor agonists, such as WIN 55,212-2 and THC, described were the favourable therapeutic ratio because of sustained efficacy and absence of tolerance, physical withdrawal, or CB1-mediated side effects [30]. Therefore, selectively targeting CB2 receptors can produce antiallodynic effects whilst bypassing the unwanted central effects associated with CB1 receptor activation [30].

### Table 3: Continued.

| Chemotherapy drug | CINP model | CB receptor agonist | Effects | Effects of CB receptor antagonists on the activity of the compound | Reference |
|-------------------|------------|---------------------|---------|-----------------------------------------------------------------|-----------|
| Cisplatin and paclitaxel | Male SD rats | AM1710 | Suppressed established mechanical and cold allodynia | CB1 antagonist AM251 had no effect | [41] |
| Paclitaxel | Male SD rats | AM1710 | Prevented the development of mechanical and cold allodynia | CB2 antagonist AM630 antagonised | [39] |
| Paclitaxel | CD1 and C57BL/6J mice | AM1710 | Suppressed established mechanical and cold allodynia | CB1 receptor antagonist AM251 had no effect | [30] |
| Paclitaxel | Male SD rats | MDA7 | Suppressed established mechanical allodynia | No antagonists were used | [42] |
| Paclitaxel | Male SD rats and mice (strain not specified) | MDA7 | Suppressed established mechanical allodynia | No antagonists were used in paclitaxel-induced mechanical allodynia | [43] |
| Paclitaxel | Male SD rats | MDA7 | Prevented the development of mechanical allodynia | No antagonists were used | [44] |
| Paclitaxel | Male SD rats and mice (strain not specified) | MDA19 | Suppressed established mechanical allodynia | No antagonists were used | [45] |
| Paclitaxel | Male C57BL/6J mice | LY2828360 | Suppressed established mechanical and cold allodynia | No antagonists were used | [46] |
| Cisplatin | Male Wistar rats | JWH133 | Suppressed established mechanical allodynia | CB2 antagonist SR144528 antagonised | [38] |
| Paclitaxel | Male Swiss mice | BCP | Suppressed established mechanical allodynia | CB1 receptor antagonist AM251 had no effect | [47] |
| Paclitaxel | Male SD rats and mice (strain not specified) | MDA19 | Suppressed established mechanical allodynia | No antagonists were used | [45] |
| Paclitaxel | Male C57BL/6J mice | LY2828360 | Suppressed established mechanical and cold allodynia | No antagonists were used | [46] |
| Cisplatin | Male Wistar rats | JWH133 | Suppressed established mechanical allodynia | CB2 antagonist SR144528 antagonised | [38] |
| Paclitaxel | Male Swiss mice | BCP | Suppressed established mechanical allodynia | CB1 receptor antagonist AM251 had no effect | [47] |

AEA, N-arachidonylethanolamine (anandamide); BCP, β-caryophyllene; PAM, positive allosteric modulator; SD, Sprague-Dawley; THC, Δ9-tetrahydrocannabinol; WIN, WIN 55,212-2.
6. Effect of the Nonpsychoactive Phytocannabinoid Cannabidiol on Chemotherapy-Induced Neuropathic Pain

The effects of the nonpsychoactive phytocannabinoid cannabidiol in mice models of CINP were evaluated in 3 studies. Different from the trend noted above, the majority of these studies (two out of three) utilised female mice (Table 4).

Cannabidiol was found to prevent the development of paclitaxel-induced cold and mechanical allodynia [49, 50]. However, in another study, cannabidiol attenuated established cisplatin-induced mechanical allodynia but could not prevent its development [31]. Cannabidiol displays low affinity for CB1 and CB2 receptors but antagonises cannabinoid CB1/CB2 receptor agonists [51]. The antiallodynic effects of cannabidiol were not blocked by either CB1 or CB2 receptor antagonists but were blocked by a 5-HT1A receptor antagonist [50].

7. Effect of Other Drugs That Affect the Endocannabinoid System on Chemotherapy-Induced Neuropathic Pain

Other drugs that produce biologic activity via other mechanisms independent of the cannabinoid system have been reported to have antiallodynic and anti-hyperalgesic activities in animal models of CINP in a cannabinoid receptor-dependent manner [52, 53]. Fifty percent of the studies (one out of two) used female animals (Table 5).

Parvathy and Masocha reported that coadministration of indomethacin and minocycline previously been reported has more antinociceptive effects in a mouse model of arthritis than when either drug alone was administered [56]. Moreover, indomethacin and minocycline are already clinically used for managing pain and inflammation in humans with conditions such as rheumatoid arthritis [57, 58]. Thus, if confirmed useful in other models of CINP, it would be easier to translate the findings to humans than with synthetic cannabinoid agonists or modulators not yet tried in the clinics.

The role of the cannabinoid receptors in the antiallodynic effects of desipramine was evaluated in mice with paclitaxel-induced mechanical and cold allodynia [52]. Desipramine is a tricyclic antidepressant used clinically in the management of neuropathic pain including CINP [59]. Cannabidiol CB1 and CB2 receptor antagonists partially attenuated the ability of desipramine to prevent the development of paclitaxel-induced mechanical and cold allodynia in these mice [52]. This study adds an understanding of other possible mechanisms of action of desipramine in the management of CINP.

8. Concluding Remarks

The endocannabinoid system is dysregulated in animal models of CINP, most notably the reduced levels of AEA and 2-AG in the paw skin, which suggest their deficiency in the periphery but not in the CNS. These findings indicate that inhibitors of FAAH and MGL could result in an elevation of the endocannabinoids and alleviation of CINP. Indeed, FAAH and MGL inhibitors have been found to prevent or attenuate symptoms of CINP in animal models. Closely related to the changes in the expression of endocannabinoids in the periphery, a peripherally acting FAAH inhibitor URB937 alleviated established CINP in rats [24]. Further research on peripherally acting FAAH and MGL inhibitors in the management of CINP is warranted, since they would lack the CNS side effects of centrally acting drugs.

Various agonists of CB1 and CB2 receptors prevent or attenuate symptoms of CINP in animal models; however, various problems are associated with CB1 receptor activation including physical dependence, development of tolerance, and other cannabimimetic adverse effects such as

| Table 4: Effects of cannabidiol in animal models of CINP. |
|----------------|----------------|----------------|----------------|----------------|
| **CINP model** | **Chemotherapy drug** | **Animal** | **Effects** | **Effects of CB receptor antagonists on the activity of the compound** | **Reference** |
| Paclitaxel | Female C57Bl6 mice | Prevented the development of cold and mechanical allodynia | No antagonists were used | [49] |
| Paclitaxel | Female C57Bl6 mice | Prevented the development of mechanical allodynia | CB1 receptor antagonist SR141716 and CB2 receptor antagonist SR144528 had no effects | [50] |
| Cisplatin | Male C57Bl6 mice | Suppressed established mechanical allodynia | 5-HT1A receptor antagonist WAY 100635 antagonised | |
hypothermia and catalepsy. Options to circumvent these problems that have been explored include the use of a CB1 receptor PAM or CB2 receptor-selective agonists. Both the CB1 receptor PAM and CB2 receptor-selective agonists attenuate CINP in animals with less adverse effects than nonselective CB1/CB2 receptor agonists, FAAH and MGL inhibitors. Thus, CB1 receptor PAMs or CB2 receptor-selective agonists warrant further research as they might have a better safety profile than the classical cannabinoids.

Cannabidiol, which is a major constituent of cannabis, attenuates allodynia in animal models of CINP, in part via 5-HT1A receptors but independent of the CB receptors. Desipramine which is a TCA used clinically in the management of CINP seems to be working partially via CB1 and CB2 receptors. This information aids in the understanding of how some of the drugs currently used to manage CINP work. The study on the coadministration of minocycline and indomethacin shows that the combination attenuates CINP in animals in a CB1 receptor-dependent manner. This study opens an avenue for modulating the endocannabinoid system for managing CINP with drugs that are already being used in the clinics for other conditions.

The studies analysed suggest that targeting the endocannabinoid system for prevention and treatment of CINP is a plausible therapeutic option. Further research is needed to ascertain whether this approach has advantages compared to already existing treatment options for CINP and whether this can be translated into clinical applications.

One striking observation is that the majority of the studies on animal models of CINP analysed in this review utilised male rodents (almost 90%). Current clinical and experimental findings show that there are sex/gender differences in the manifestation and mechanisms involved in pain including CINP [60–63]. Moreover, sex/gender differences in both the expression of endocannabinoids and antinociceptive activity of cannabinoids have been reported [64, 65]. A consensus report published by members of the Sex, Gender and Pain Special Interest Group of the International Association for the Study of Pain recommended that “all pain researchers consider testing their hypotheses in both sexes, or if restricted by practical considerations, only in females” [66]. This is important because of the higher prevalence of some types of pain in females compared to males, the gender differences in response to analgesics both in experimental animals and humans, and the higher number of studies done in male than in female models of pain [66]. Taking this into consideration, it is imperative that future studies on CINP utilise more female models.

### Table 5: Effects of other agents, in a CB receptor-dependent manner, in animal models of CINP.

| Chemotherapy drug | Animal | Molecule | Effects | Effects of CB receptor antagonists on the activity of the compound | Reference |
|------------------|--------|----------|---------|-------------------------------------------------------------|-----------|
| Paclitaxel       | Female and male BALB/c mice | Indomethacin (NSAID) plus minocycline (semisynthetic tetracycline antibiotic) | Reduced established thermal hyperalgesia | CB1 antagonist AM251 antagonised | [53] |
| Paclitaxel       | Male Sprague-Dawley rats | Desipramine (tricyclic antidepressant) | Prevented the development of mechanical and cold allodynia | CB1 antagonist AM251 and CB2 antagonist AM630 partially antagonised | [52] |

NSAID, nonsteroidal anti-inflammatory drug.

### Conflicts of Interest

The author declares that there are no conflicts of interest.

### References

[1] M. Seretny, G. L. Currie, E. S. Sena et al., “Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis,” *Pain*, vol. 155, no. 12, pp. 2461–2470, 2014.

[2] C. C. Reyes-Gibby, P. K. Morrow, A. Buzdar, and S. Shete, “Chemotherapy-induced peripheral neuropathy as a predictor of neuropathic pain in breast cancer patients previously treated with paclitaxel,” *Journal of Pain*, vol. 10, no. 11, pp. 1146–1150, 2009.

[3] A. J. Rampen, J. L. Jongen, I. van Heuvel, M. Scheltens-de Boer, P. Sonneveld, and M. J. van den Bent, “Bortezomib-induced polyneuropathy,” *Netherlands Journal of Medicine*, vol. 71, pp. 128–133, 2013.

[4] P. M. Dougherty, J. P. Cata, J. V. Cordella, A. Burton, and H. R. Weng, “Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients,” *Pain*, vol. 109, no. 1, pp. 132–142, 2004.

[5] F. H. Hausheer, R. L. Schilsky, S. Bain, E. J. Berghorn, and F. Lieberman, “Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy,” *Seminars in Oncology*, vol. 33, no. 1, pp. 15–49, 2006.

[6] S. Wolf, D. Barton, L. Kotrotsou, A. Grothey, and C. Loprinzi, “Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies,” *European Journal of Cancer*, vol. 44, no. 11, pp. 1507–1515, 2008.

[7] D. L. Herschman, C. Lacchetti, R. H. Dworkin et al., “Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline,” *Journal of Clinical Oncology*, vol. 32, no. 18, pp. 1941–1967, 2014.

[8] D. I. Abrams, “Using medical cannabis in an oncology practice,” *Oncology*, vol. 30, no. 5, pp. 397–404, 2016.

[9] D. I. Abrams, “Integrating cannabis into clinical cancer care,” *Current Oncology*, vol. 23, no. 2, pp. S8–S14, 2016.

[10] D. I. Abrams, C. A. Jay, S. B. Shade et al., “Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial,” *Neurology*, vol. 68, no. 7, pp. 515–521, 2007.
Pain Research and Management

[11] P. F. Whiting, R. F. Wolff, S. Deshpande et al., “Cannabinoids for medical use: a systematic review and meta-analysis,” JAMA, vol. 313, no. 24, pp. 2456–2473, 2015.

[12] M. E. Lynch, P. Cesar-Rittenberg, and A. G. Hohmann, “A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain,” Journal of Pain and Symptom Management, vol. 47, no. 1, pp. 166–173, 2014.

[13] J. Guindon and A. G. Hohmann, “The endocannabinoid system and pain,” CNS & Neurological Disorders–Drug Targets, vol. 8, no. 6, pp. 403–421, 2009.

[14] A. Giuffrida, L. H. Parsons, T. M. Kerr, F. Rodriguez de Fonseca, M. Navarro, and D. Piomelli, “Dopamine activation of endogenous cannabinoid signaling in dorsal striatum,” Nature Neuroscience, vol. 2, no. 4, pp. 358–363, 1999.

[15] J. Kim, M. Isokawa, C. Ledent, and B. E. Alger, “Activation of muscarinic acetylcholine receptors enhances the release of endogenous cannabinoids in the hippocampus,” Journal of Neuroscience, vol. 22, no. 23, pp. 10182–10191, 2002.

[16] A. Luchicchi and M. Pistis, “Anandamide and 2-arachidonoylglylycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids,” Molecular Neurobiology, vol. 46, no. 2, pp. 374–392, 2012.

[17] N. Varma, G. C. Carlson, C. Ledent, and B. E. Alger, “Metabotropic glutamate receptors drive the endocannabinoid system in hippocampus,” Journal of Neuroscience, vol. 21, no. 24, p. RC188, 2001.

[18] V. Di Marzo, T. Bisogno, T. Sugiuira, D. Melck, and L. De Petrocellis, “The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide,” Biochemical Journal, vol. 331, no. 1, pp. 15–19, 1998.

[19] D. Piomelli, “The endocannabinoid system: a drug discovery perspective,” Current Opinion in Investigational Drugs, vol. 6, no. 7, pp. 672–679, 2005.

[20] V. Di Marzo, “Targeting the endocannabinoid system: to enhance or reduce?,” Nature Reviews Drug Discovery, vol. 7, no. 5, pp. 438–455, 2008.

[21] B. F. Cravatt, D. K. Giang, S. P. Mayfield, D. L. Boger, R. A. Lerner, and N. B. Gilula, “Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides,” Nature, vol. 384, no. 6604, pp. 83–87, 1996.

[22] T. P. Dinh, D. Carpenter, F. M. Leslie et al., “Brain monoacylglyceride lipase participating in endocannabinoid inactivation,” Proceedings of the National Academy of Sciences, vol. 99, no. 16, pp. 10819–10824, 2002.

[23] S. M. Saario, J. R. Savinainen, J. T. Laitinen, T. Jarvinen, and R. Niemi, “Monoacylglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes,” Biochemical Pharmacology, vol. 67, no. 7, pp. 1381–1387, 2004.

[24] J. Guindon, Y. Lai, S. M. Takacs, H. B. Bradshaw, and A. G. Hohmann, “Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment,” Pharmacological Research, vol. 67, no. 1, pp. 94–109, 2013.

[25] I. A. Khasabova, S. Khasabov, J. Paz, C. Harding-Rose, D. A. Simone, and V. S. Seybold, “Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy,” Journal of Neuroscience, vol. 32, no. 20, pp. 7091–7101, 2012.

[26] I. A. Khasabova, X. Yao, J. Paz et al., “JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy,” Pharmacological Research, vol. 90, pp. 67–75, 2014.

[27] M. L. Uhelski, I. A. Khasabova, and D. A. Simone, “Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy,” Journal of Neurophysiology, vol. 113, no. 5, pp. 1501–1510, 2015.

[28] A. Caprioli, R. Coccurello, C. Rapino et al., “The novel reversible fatty acid hydrolase inhibitor ST4070 increases endocannabinoid brain levels and counteracts neuropathic pain in different animal models,” Journal of Pharmacology and Experimental Therapeutics, vol. 342, no. 1, pp. 188–195, 2012.

[29] R. A. Slivicki, Z. Xu, P. M. Kulkarni et al., “Positive allosteric modulation of cannabinoid receptor type 1 suppresses pathological pain without producing tolerance or dependence,” Biological Psychiatry, 2017.

[30] L. Deng, J. Guindon, B. L. Cornett, A. Makriyannis, K. Mackie, and A. G. Hohmann, “Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal,” Biological Psychiatry, vol. 77, no. 5, pp. 475–487, 2015.

[31] H. M. Harris, K. J. Suflka, W. Gul, and M. A. ElSohly, “Effects of delta-9-tetrahydrocannabinol and cannabinol on cisplatin-induced neuropathy in mice,” Planta Medica, vol. 82, no. 13, pp. 1169–1172, 2016.

[32] L. Deng, B. L. Cornett, K. Mackie, and A. G. Hohmann, “CB1 knockout mice unveil sustained CB2-mediated antiallodynic effects of the mixed CB1/CB2 agonist CP55,940 in a mouse model of paclitaxel-induced neuropathic pain,” Molecular Pharmacology, vol. 88, no. 1, pp. 64–74, 2015.

[33] D. Pascual, C. Goicoechea, M. Suardiaz, and M. I. Martin, “A cannabinoid agonist, WIN 55,212-2, reduces neuropathic nociception induced by paclitaxel in rats,” Pain, vol. 118, no. 1, pp. 23–34, 2005.

[34] E. J. Rahn, A. Makriyannis, and A. G. Hohmann, “Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats,” British Journal of Pharmacology, vol. 152, no. 5, pp. 765–777, 2007.

[35] G. Vera, A. Chiarlone, P. A. Cabezos, D. Pascual, M. I. Martin, and R. Abalo, “WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat,” Life Sciences, vol. 81, no. 6, pp. 468–479, 2007.

[36] E. Burgos, D. Gomez-Nicola, D. Pascual, M. I. Martin, M. Nieto-Sampedro, and C. Goicoechea, “Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells,” European Journal of Pharmacology, vol. 682, no. 1–3, pp. 62–72, 2012.

[37] R. Abalo, P. A. Cabezos, G. Vera, A. E. Lopez-Perez, and M. I. Martin, “Cannabinoids may worsen gastric dysmotility induced by chronic cisplatin in the rat,” Neurogastroenterology & Motility, vol. 25, no. 5, pp. e292–e382, 2013.

[38] G. Vera, P. A. Cabezos, M. I. Martin, and R. Abalo, “Characterization of cannabinoid-induced relief of neuropathic pain in a rat model of cisplatin-induced neuropathy,” Pharmacology, Biochemistry, and Behavior, vol. 105, pp. 205–212, 2013.
[39] E. J. Rahn, L. Deng, G. A. Thakur et al., "Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery," *Molecular Pain*, vol. 10, p. 27, 2014.

[40] E. J. Rahn, A. M. Zvonok, G. A. Thakur, A. D. Khanolkar, A. Makriyannis, and A. G. Hohmann, "Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats," *Journal of Pharmacology and Experimental Therapeutics*, vol. 327, no. 2, pp. 584–591, 2008.

[41] L. Deng, J. Guindon, V. K. Vemuri et al., "The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy," *Molecular Pain*, vol. 8, p. 71, 2012.

[42] M. Naguib, P. Diaz, J. J. Xu et al., "MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models," *British Journal of Pharmacology*, vol. 155, no. 7, pp. 1104–1116, 2008.

[43] M. Naguib, J. J. Xu, P. Diaz et al., "Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system," *Anesthesia and Analgesia*, vol. 114, no. 5, pp. 1104–1120, 2012.

[44] J. J. Xu, P. Diaz, B. Bie et al., "Spinal gene expression profiling and pathways analysis of a CB2 agonist (MDA7)-targeted prevention of paclitaxel-induced neuropathy," *Neuroscience*, vol. 260, pp. 185–194, 2014.

[45] J. J. Xu, P. Diaz, F. Austric-Diaz, S. Craig, E. Munoz, and M. Naguib, "Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain," *Anesthesia and Analgesia*, vol. 111, no. 1, pp. 99–109, 2010.

[46] X. Lin, A. S. Dhopeshwarkar, M. Huibregtse, K. Mackie, and A. G. Hohmann, "Slowly signaling G protein-biased CB2 cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence," *Molecular Pharmacology*, vol. 93, no. 2, pp. 49–62, 2018.

[47] G. C. Segat, M. N. Manjavachi, D. O. Matias et al., "Anti-allodynic effect of beta-caryophyllene on paclitaxel-induced peripheral neuropathy in mice," *Neuropharmacology*, vol. 125, pp. 207–219, 2017.

[48] J. Gertsch, M. Leonti, S. Raduner et al., "Beta-caryophyllene is a dietary cannabinoid," *Proceedings of the National Academy of Sciences*, vol. 105, no. 26, pp. 9099–9104, 2008.

[49] S. J. Ward, S. D. Ramirez, H. Neelakantan, and E. A. Walker, "Cannabinidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice," *Anesthesia and Analgesia*, vol. 113, no. 4, pp. 947–950, 2011.

[50] S. J. Ward, S. D. McAllister, R. Kawamura, R. Murase, H. Neelakantan, and E. A. Walker, "Cannabinidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy," *British Journal of Pharmacology*, vol. 171, no. 3, pp. 636–645, 2014.

[51] R. G. Pertwee, "The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin," *British Journal of Pharmacology*, vol. 153, no. 2, pp. 199–215, 2008.

[52] L. Deng, W. H. Lee, Z. Xu, A. Makriyannis, and A. G. Hohmann, "Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems," *Pharmacological Research*, vol. 114, pp. 75–89, 2016.

[53] S. S. Parvathy and W. Masocha, "Co-administration of indomethacin and minocycline attenuates established paclitaxel-induced neuropathic thermal hyperalgesia: involvement of cannabinoid CB1 receptors," *Scientific Reports*, vol. 5, no. 1, article 10541, 2015.

[54] L. Guasti, D. Richardson, M. Jhaveri et al., "Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain," *Molecular Pain*, vol. 5, p. 35, 2009.

[55] H. Guhring, M. Hamza, M. Sergejeva et al., "A role for endocannabinoids in indomethacin-induced spinal anti-nociception," *European Journal of Pharmacology*, vol. 454, no. 2-3, pp. 153–163, 2002.

[56] A. A. Abu-Ghefreh and W. Masocha, "Enhancement of antinociception by co-administration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in naive mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis," *BMC Musculoskeletal Disorders*, vol. 11, no. 1, p. 276, 2010.

[57] N. Garrido-Mesa, A. Zarzuelo, and J. Galvez, "Minocycline: far beyond an antibiotic," *British Journal of Pharmacology*, vol. 169, no. 2, pp. 337–352, 2013.

[58] S. Nalamachu and R. Wörtmann, "Role of indomethacin in acute pain and inflammation management: a review of the literature," *Postgraduate Medicine*, vol. 126, no. 4, pp. 92–97, 2014.

[59] D. R. Pachman, D. L. Barton, J. C. Watson, and C. L. Loprinzi, "Chemotherapy-induced peripheral neuropathy: prevention and treatment," *Clinical Pharmacology and Therapeutics*, vol. 90, no. 3, pp. 377–387, 2011.

[60] R. B. Fillingim, C. D. King, M. C. Ribeiro-Dasilva, B. Rahim-Williams, and J. L. Riley, "Sex, gender, and pain: a review of recent clinical and experimental findings," *Journal of Pain*, vol. 10, no. 5, pp. 447–485, 2009.

[61] J. C. Mapplebeck, S. Beggs, and M. W. Salter, "Sex differences in pain: a tale of two immune cells," *Pain*, vol. 157, no. 1, pp. 52–56, 2016.

[62] H. Naji-Esfahani, G. Vaseghi, L. Safaeian, A. A. Pilevarian, A. Abed, and M. Rafieian-Kopaei, "Gender differences in a mouse model of chemotherapy-induced neuropathic pain," *Laboratory Animals*, vol. 50, no. 1, pp. 15–20, 2016.

[63] D. Ruau, L. Y. Liu, J. D. Clark, M. S. Angst, and A. J. Butte, "Sex differences in reported pain across 11,000 patients captured in electronic medical records," *Journal of Pain*, vol. 13, no. 3, pp. 228–234, 2012.

[64] H. B. Bradshaw, N. Rimmerman, J. F. Krey, and J. M. Walker, "Sex and hormonal cycle differences in rat brain levels of pain-related cannabimimetic lipid mediators," *American Journal of Physiology Regulatory, Integrative and Comparative Physiology*, vol. 291, no. 2, pp. R349–R358, 2006.

[65] R. M. Craft, J. A. Marusich, and J. L. Wiley, "Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system?", *Life Sciences*, vol. 92, no. 8-9, pp. 476–481, 2013.

[66] J. D. Greenspan, R. M. Craft, L. LeResche et al., "Studying sex and gender differences in pain and analgesia: a consensus report," *Pain*, vol. 132, no. 1, pp. S26–S45, 2007.